Acclarent
Acclarent Inc. develops and commercializes minimally invasive ENT surgical devices, including the pioneering Balloon Sinuplasty system and the AI-enhanced TruDi Navigation System, sold to hospitals and surgical centers. Founded in 2004 and currently a subsidiary of Integra LifeSciences (acquired April 2024).
- Company typePrivate
- Founded2004
- HeadquartersMenlo Park, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Acclarent does
Acclarent Inc. is a medical device company that develops and commercializes minimally invasive technologies for the treatment of ear, nose, and throat (ENT) disorders, primarily chronic sinusitis. Founded in 2004 and headquartered in Menlo Park, California, the company pioneered Balloon Sinuplasty, a balloon sinus dilation technique that opened an alternative to traditional invasive sinus surgery, and later developed the TruDi Navigation System, an AI-enhanced surgical navigation platform that provides real-time instrument tracking during sinus procedures. The company holds FDA 510(k) clearances for its devices and serves hospitals and surgical centers performing ENT surgery through a direct enterprise field sales model.
Acclarent was originally venture-backed by Versant Ventures, New Enterprise Associates, Meritech Capital Partners, Delphi Ventures, and Johnson & Johnson Development Corporation, raising approximately $86 million across funding rounds from 2004 to 2009 before being acquired by Johnson & Johnson (via Ethicon) in 2010. Under J&J ownership, Acclarent operated as a division for over a decade, contributing to the J&J/Acclarent 14% share of the global ENT Surgical Devices market (valued at USD 3.487 billion in 2026), trailing Medtronic at 18%. In April 2024, Integra LifeSciences Holdings Corporation completed the acquisition of Acclarent from Ethicon, integrating it into Integra's surgical device portfolio.
The TruDi Navigation System was enhanced with AI algorithms in late 2021, after which FDA adverse event reports increased sharply — from roughly 8 malfunctions over three years to more than 100 — including strokes, cerebrospinal fluid leaks, and skull punctures. Two patients have filed lawsuits in Texas alleging the AI component caused surgical errors and injuries, representing a material regulatory and litigation exposure that affects the company's AI product trajectory and overall risk profile.
Acclarent firmographics
Firmographics- Name
- Acclarent
- Legal name
- Acclarent Inc.
- Website
- https://acclarent.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Acclarent Inc. develops and commercializes minimally invasive ENT surgical devices, including the pioneering Balloon Sinuplasty system and the AI-enhanced TruDi Navigation System, sold to hospitals and surgical centers. Founded in 2004 and currently a subsidiary of Integra LifeSciences (acquired April 2024).
- Ownership category
- akta.pro rank
Acclarent industry classification
Industry- Product category
- ENT Surgical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)
- akta.pro secondary industries
- General Otolaryngology (ENT) (HLAKAMAA), ENT / Otolaryngology Surgery Centers (HLAFAIAJ), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)
Keywords
Where Acclarent is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Markets served
Acclarent business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Hardware Sales: Sale of ENT surgical devices including the TruDi Navigation System and Balloon Sinuplasty products to hospitals and surgical centers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Acclarent product offering
Product offeringCore offering
Acclarent develops and sells minimally invasive medical devices for ear, nose, and throat (ENT) surgical procedures, with a primary focus on chronic sinusitis treatment. Its flagship offerings are the Balloon Sinuplasty system, a pioneering balloon sinus dilation technology, and the TruDi Navigation System, an AI-enhanced image-guided surgical navigation platform. These devices are sold to hospitals, surgical centers, and ENT surgeons for use in sinus and related ENT procedures.
Product overview
Acclarent, now a division of Integra LifeSciences, offers a portfolio of minimally invasive ENT treatments centered around two key products: Balloon Sinuplasty (their pioneering balloon sinus dilation technology) and the TruDi Navigation System (an AI-enhanced surgical navigation system for sinus surgery). The company was originally founded in 2004 and acquired by Johnson & Johnson in 2010, then acquired by Integra LifeSciences in April 2024.
Differentiator
Problem solved
Functional benefit
Brands
- Balloon Sinuplasty: Minimally invasive ENT treatment technology pioneered by Acclarent.
- TruDi Navigation System
Products and services
- Balloon Sinuplasty A pioneering minimally invasive balloon sinus dilation system used by ENT surgeons to open blocked sinus passages in patients with chronic sinusitis, offering an alternative to traditional invasive sinus surgery with reduced patient recovery time.
- TruDi Navigation System An AI-enhanced image-guided surgical navigation system used by ENT surgeons during sinus surgery procedures to track surgical instrument locations in real time. The system received AI algorithm enhancements in late 2021.
Companies that use Acclarent
Customer profileSegments1 record
Ideal customer profiles1 record
Acclarent technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Acclarent partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered major.
- Integra LifeSciencesmajorIn April 2024, Integra LifeSciences Holdings Corporation completed the acquisition of Acclarent Inc. from Ethicon (Johnson & Johnson), expanding its surgical device offerings through Acclarent's ENT technologies including the TruDi Navigation System.
- Johnson & JohnsonmajorAcclarent was acquired by Johnson & Johnson in 2010, becoming a division of J&J. The company was originally founded with Fund II in 2004 and pioneered Balloon Sinuplasty technology. J&J held approximately 14% global market share in ENT surgical devices.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Acclarent competitors and assessment
Company assessmentDirect peers
- Medtronic: Medtronic is the global leader in ENT surgical devices with ~18% share vs. Acclarent's ~14%, directly competing in sinus surgery navigation, powered instruments, and balloon dilation.
- Intersect ENT: Intersect ENT (now part of Medtronic) developed sinus drug-eluting implants and propels steroid implants, directly adjacent to Acclarent's minimally invasive sinus treatment franchise.
- Spirox / Entellus Medical (Stryker): Entellus (acquired by Stryker) and Spirox focused on in-office balloon sinus dilation systems, directly competing with Acclarent's Balloon Sinuplasty platform.
- Karl Storz SE & Co. KG: Karl Storz is a leading ENT endoscopy and instrument specialist directly comparable to Acclarent's surgical device portfolio for sinus and otolaryngology procedures.
Broad incumbents
- Smith+Nephew: Smith+Nephew is a diversified surgical device incumbent with ENT-adjacent offerings and shared hospital sales channels overlapping Acclarent's enterprise field sales motion.
- Stryker: Stryker is a diversified surgical device incumbent whose ENT and navigation offerings overlap with Acclarent's TruDi system across hospital surgical suites.
- Olympus Corporation: Olympus is a major player in ENT endoscopy and rigid scopes used in sinus surgery, providing overlapping equipment to the same otolaryngology surgical centers Acclarent serves.
Others
- Integra LifeSciences: Integra LifeSciences is Acclarent's parent company (acquired April 2024), operating the ENT surgical portfolio alongside neurosurgery and regenerative technology franchises.
- Johnson & Johnson (Ethicon): Ethicon, J&J's surgical device division, owned Acclarent from 2010 to 2024 and continues to operate in overlapping surgical device categories with shared hospital customers.
Emerging players
- Sinusys Corporation: Sinusys is an emerging player in sinus dilation and drug delivery technologies, competing in the same balloon sinuplasty category Acclarent pioneered.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Acclarent social profiles
Digital presenceAcclarent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acclarent leadership team
Management profileNumber of profiles
Acclarent funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acclarent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acclarent
What does Acclarent do?
Acclarent develops and sells minimally invasive medical devices for ear, nose, and throat (ENT) surgical procedures, with a primary focus on chronic sinusitis treatment. Its flagship offerings are the Balloon Sinuplasty system, a pioneering balloon sinus dilation technology, and the TruDi Navigation System, an AI-enhanced image-guided surgical navigation platform. These devices are sold to hospitals, surgical centers, and ENT surgeons for use in sinus and related ENT procedures.
Is Acclarent a public or private company?
Acclarent is a private company. It is classified as corporate owned and is currently operating.
When was Acclarent founded?
Acclarent was founded in 2004. It employs 251 to 500 people.
Where is Acclarent based?
Acclarent is headquartered in Menlo Park, United States, in the North America region.
How does Acclarent make money?
One revenue line is on record: medical Device Hardware Sales.
Who are Acclarent's main competitors?
Direct peers on record are Medtronic, Intersect ENT, Spirox / Entellus Medical (Stryker) and Karl Storz SE & Co. KG. Broad incumbents are Smith+Nephew, Stryker and Olympus Corporation. Others are Integra LifeSciences and Johnson & Johnson (Ethicon). Sinusys Corporation is listed as an emerging player.
Does Acclarent have an API?
No public API is recorded for Acclarent.
What industry is Acclarent in?
Acclarent's product category is ENT Surgical Devices. Its primary akta.pro industry code is HLAHADAG, Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT), with a secondary code of HLAKAMAA, General Otolaryngology (ENT). Its NAICS code is 339112 and its SIC code is 3841.